BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xia S, Ji L, Tao L, Pan Y, Lin Z, Wan Z, Pan H, Zhao J, Cai L, Xu J, Cai X. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance. Cell Mol Gastroenterol Hepatol 2021;12:1121-43. [PMID: 33962073 DOI: 10.1016/j.jcmgh.2021.04.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Jo S, Samarpita S, Lee JS, Lee YJ, Son JE, Jeong M, Kim JH, Hong S, Yoo S, Kim W, Rasool M, Byun S. 8-Shogaol Inhibits Rheumatoid Arthritis through Targeting TAK1. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106176] [Reference Citation Analysis]
2 Pietrobono S, Melisi D. A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib. Cell Mol Gastroenterol Hepatol 2021;12:1151-2. [PMID: 34181901 DOI: 10.1016/j.jcmgh.2021.06.005] [Reference Citation Analysis]
3 Yeung CLS, Yam JWP. Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.02.013] [Reference Citation Analysis]